Founded in 2017 in Duesseldorf, Germany, Numaferm has become a trusted partner in the field of the recombinant expression of peptides, pepteins and proteins. Our team of ~ 30 experts is built to solve all challenges along the way from discovery to commercialization. With more than 15 Ph. D. level scientists and cumulated relevant experiences of + 100 years, highest scientific expertise is guaranteed. Our facility of 500 m2 (5,300 ft2) is equipped with state-of-the-art technology ensuring industry-grade processes and GMP/commercial production at third party CMOs. Quality and customer satisfaction is of highest importance and we are operating in accordance to the ISO9001:2015 standards. Our technologies and our operations were recognized by national and international media and awarded with prestigious prices.
to left
to right
Chief Executive Officer
Dr. Roland Hecht
CEO
Chief Scientific Officer
Dr. Christian Schwarz
CSO & Co-Founder of Numaferm GmbH
Advisory Board
Dr. Anke Caßing
Senior Investment Manager,
High-Tech-Gründerfonds
Dr. Jens Busse
Investment Manager,
Evonik Ventures
Dr. Klaus Binder
CEO & Founder,
Binder Associates
Robert E. W. Hancock
Killam Professor Microbiology / Immunology,
University of British Columbia
Dr. Jürgen Schumacher
Business Angel & Serial Entrepreneur,
i.e. Qiagen and NewLab
Dr. Karl-Heinz Maurer
Chairman of the Board,
CLIB
Prof. Dirk Lütkemeyer
University of Bielefeld,
Co-founder Bibitec
Prof. em. Dr. Dr. h.c. Detlev Riesner
Business Angel & Serial Entrepreneur,
i.e. Qiagen and Evotec
Prof. Dr. Karl-Erich Jaeger
Forschungszentrum Jülich/HHU,
Co-founder evoxx
Prof. Dr. Lutz Schmitt
Chair Biochemistry I,
Heinrich-Heine-Universität Düsseldorf
Alain Scarso, PhD
Peptide CMO expert,
i.e. Polypeptide and Lonza (retired)